FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial ...

The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment ...

The applications of AI virtual human technology are rapidly expanding, demonstrating its value in social good and ...

In total, 11 abstracts on givinostat were accepted for presentation at the Congress, including two for an oral presentation ...

In its complete response letter, the FDA cited insufficient evidence establish deramiocel's effectiveness for cardiomyopathy ...

TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.

Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...

Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...

The FDA has rejected Capricor Therapeutics’ filing for approval of a Duchenne muscular dystrophy (DMD) cell therapy, raising ...

Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular ...

Taiho-developed TAS-205 is designed to selectively inhibit hematopoietic prostaglandin D synthase (HPGDS), an enzyme related ...